Study to Evaluate Imetelstat (GRN163L) in Participants With International Prognostic Scoring System (IPSS) Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS)
This research study is investigating a new medication called imetelstat for people with a specific type of blood disorder called Myelodysplastic Syndromes (MDS). Specifically, it's for those with lower-risk MDS who need regular blood transfusions and whose previous treatment (erythropoiesis-stimulating agents, or ESAs) is no longer effective. The study has two main parts: Phase 2, which looks at how well imetelstat works and its safety, and Phase 3, which compares imetelstat to a dummy drug (placebo) to see if it can help patients become less reliant on blood transfusions. There's also a long-term follow-up to understand the drug's extended effects.
Em resumo
Resultados
Resultados deste estudo
Publicado February 2025Os resultados foram publicados para este estudo.
Sobre o que é este estudo?
This study is looking into a new medication called imetelstat for people living with Myelodysplastic Syndromes (MDS). MDS is a condition where the bone marrow, which is the spongy tissue inside some bones, doesn’t make enough healthy blood cells. Many people with MDS, especially those with lower-risk types, need regular blood transfusions to top up their red blood cells. Often, they first try treatments called erythropoiesis-stimulating agents (ESAs) to help their body make more red blood cells on its own. This study is specifically for those who still need transfusions even after trying ESAs, or for whom ESAs are no longer working.
The main goal of this study is to find out if imetelstat can help people with MDS reduce or even stop their need for blood transfusions. To do this, the study is split into two phases. The first part, Phase 2, focused on understanding how effective imetelstat is and what its side effects might be. The second, larger part, Phase 3, is comparing imetelstat directly with a placebo (a dummy drug that looks like the real thing but has no active ingredients). This comparison helps researchers determine if any improvements seen are truly due to imetelstat rather than other factors. There's also a special smaller study looking at how imetelstat might affect the heart's electrical activity.
For those who seem to benefit from imetelstat during the main study, there's an optional extension phase. This allows patients to continue receiving the treatment for a longer period. This extension is crucial for gathering information on the long-term safety of imetelstat, how long its benefits last, and to monitor for any changes in the condition, including if it progresses into a more aggressive form of leukaemia.
Pontos principais
- The study is for adults with a specific type of Myelodysplastic Syndrome (MDS).
- It's for people who need regular blood transfusions and whose previous treatment didn't work well.
- The main goal is to see if a new drug, imetelstat, can reduce the need for blood transfusions.
- Some participants will receive imetelstat, while others might receive a placebo.
- Participation involves regular clinic visits for tests and monitoring over several years.
- Você pode parar de participar do estudo a qualquer momento.
Quem pode ser elegível?
To be considered for this study, you would generally need to be an adult, aged 18 or older, with a confirmed diagnosis of Myelodysplastic Syndrome (MDS). Your MDS should be categorised as 'low' or 'intermediate-1' risk according to standard medical guidelines. A key requirement is that you also need to be dependent on regular red blood cell transfusions, meaning you've had at least four transfusions over an eight-week period in the lead-up to the study. Your general health and ability to carry out daily activities, as assessed by a doctor, should be good enough to participate.
There are also some reasons why you might not be able to join. For example, if you've had a known allergy to imetelstat or its ingredients, or if you've previously taken imetelstat. You also couldn't have participated in another research study involving an experimental drug or device within the last month. Certain recent treatments, like high-dose steroids, specific growth factors, or certain chemotherapy and immune-modifying drugs within the last four to eight weeks, would also make you ineligible. For the Phase 3 part of the study, if you've previously been treated with certain other MDS medications like hypomethylating agents or lenalidomide, you would not be able to join.
Este estudo pode ser adequado para você?
Responda a estas perguntas rápidas para ver se você pode ser elegível. Este é apenas um guia — a decisão final é da equipe de pesquisa.
- Você tem 18 anos ou mais?
- Do you have a diagnosis of 'low' or 'intermediate-1' risk MDS?
- Do you regularly need red blood cell transfusions (at least 4 units in the last 8 weeks)?
- Has your previous treatment (like ESA) not worked well or stopped working?
- Have you not received specific other MDS treatments recently?
- Are you generally well enough to participate in a study?
O que envolve a participação?
If you decide to take part in this study, you would first go through a screening process to ensure you meet all the requirements. Once enrolled, you would receive either imetelstat or a placebo (in Phase 3 or the heart study) as an infusion. The study involves regular visits to the clinic for assessments, which will include blood tests, bone marrow checks, and other evaluations of your health and how the treatment is affecting you. For those in the Phase 3 part and the heart study, you wouldn't know whether you're receiving the active drug or the placebo; this is called 'double-blind'. If you are doing well and benefitting from the treatment, you could have the option to continue receiving imetelstat in an 'Extension Phase' for up to five years from your first dose. Throughout your participation, your study doctor and team would monitor your progress and any side effects. You are free to withdraw from the study at any time.
Riscos e benefícios potenciais
Locations (126)
- UAB Comprehensive Cancer CenterCódigo postal verificadoBirmingham, Estados Unidos
- Acrc/Arizona Clinical Research, Inc.Código postal verificadoTucson, Estados Unidos
- CBCC Global Research, Inc.Código postal verificadoBakersfield, Estados Unidos
- UCLA Ronald Regan Medical CenterCódigo postal verificadoLos Angeles, Estados Unidos
- Yale-New Haven Hospital (YNHH) - Smilow Cancer HospitalCódigo postal verificadoNew Haven, Estados Unidos
- BRCR Medical CenterCódigo postal verificadoPlantation, United States
- University of South Florida (USF) - H. Lee Moffitt Cancer CenterCódigo postal verificadoTampa, Estados Unidos
- Franciscan HealthCódigo postal verificadoIndianápolis, Estados Unidos
- St. Agnes Healthcare, IncCódigo postal verificadoBaltimore, Estados Unidos
- Center for Cancer and Blood DisordersCódigo postal verificadoBethesda, Estados Unidos
- Faculdade de Medicina da Universidade de WashingtonCódigo postal verificadoSt Louis, Estados Unidos
- University of New Mexico Cancer CenterCódigo postal verificadoAlbuquerque, United States
Perguntas frequentes
What is Myelodysplastic Syndrome (MDS)?
MDS is a condition where your bone marrow doesn't produce enough healthy blood cells, leading to issues like anaemia, easy bleeding, or infections.
What does 'transfusion-dependent' mean?
It means you regularly need blood transfusions to keep your red blood cell count at a healthy level because your body isn't making enough on its own.
What is imetelstat?
Imetelstat is a new investigational drug being tested to see if it can help people with MDS reduce their need for blood transfusions.
O que é um 'placebo'?
A placebo is an inactive substance or dummy treatment that looks just like the real drug but contains no active ingredients. It's used in some studies to compare against the real drug.
Posso parar de participar do estudo a qualquer momento?
Yes, absolutely. Your participation is voluntary, and you can withdraw from the study at any point without it affecting your standard medical care.
Como saber mais
Sempre consulte seu médico ou especialista antes de decidir participar de um estudo.
Discussão
Discussão da comunidade
Desenvolvido pelo nosso fórum em community.patient.info. Por favor, seja respeitoso — isto não é um conselho médico.